Tiziana life sciences announces initiation of clinical trial in a secondary progressive multiple sclerosis (spms) patient with nasal administration of foralumab, a fully human anti-cd3 monoclonal antibody, under an individual patient expanded access program

New york and london, may 25, 2021 (globe newswire) -- tiziana life sciences plc (nasdaq: tlsa, lse: tils) (“tiziana” or the “company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to announce that the first patient with secondary progressive multiple sclerosis (spms) was dosed with nasally administered foralumab, a fully human anti-cd3 monoclonal antibody, at the brigham and women's hospital (bwh), harvard medical school, boston, ma. nasal foralumab 50 mcg (25 mcg/nostril) will be administered in 3-week cycles, with 3 times/week dosing for the first 2 weeks followed by 1 week of rest period. this first-ever clinical study in spms patients, under an individual patient expanded access ind, will continue for six months to evaluate routine safety, tolerability, and neurological behaviors. the study will also examine microglial activation, by positron emission tomography (pet), immunological and neurodegenerative markers to assess clinical responses following the treatment regimen.
TLSA Ratings Summary
TLSA Quant Ranking